- ►physiology.org JJ Holst - Physiological reviews, 2007 - Am Physiological Soc Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal
epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed
in these cells. The current knowledge regarding regulation of proglucagon gene ... Cited by 119 - Related articles - BL Direct - All 5 versions
AJ Garber, JE Foley, MA Banerji, P Ebeling, … - Diabetes Obes …, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 37 - Related articles - All 4 versions
PL Brubaker - Trends in Endocrinology & Metabolism, 2007 - Elsevier The physiological incretins, glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), lower blood glucose levels through multiple mechanisms, including
enhancement of glucose-stimulated insulin secretion. Although of demonstrated benefit to ... Cited by 13 - Related articles - All 6 versions
B Ahrén - Expert Opin. Emerging Drugs, 2008 - informahealthcare.com Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like
peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion
and inhibits glucagon secretion, resulting in lowering of glucose levels and improvement ... Cited by 7 - Related articles - All 8 versions
PE Cryer, L Axelrod, AB Grossman, SR Heller, … - Journal of Clinical …, 2009 - Endocrine Soc Conclusions: We recommend evaluation and management of hypoglycemia only in patients
in whom Whipple's triad—symptoms, signs, or both consistent with hypoglycemia, a low plasma
glucose concentration, and resolution of those symptoms or signs after the plasma ... Cited by 4 - Related articles - All 3 versions
J de Heer, C Rasmussen, DH Coy, JJ Holst - Diabetologia, 2008 - Springer Abstract Aims/hypothesis The glucose-lowering effect of glucagon- like peptide-1 (GLP-1) is
based not only upon its potent insulinotropic actions but also on its ability to restrain glucagon
secretion. Surprisingly, the closely related glucose-dependent insulinotropic peptide ... Cited by 5 - Related articles - All 2 versions
- ►physiology.org LE Fridlyand, MC Harbeck, MW Roe, LH … - American Journal of …, 2007 - Am Physiological Soc In this report we describe a mathematical model for the regulation of cAMP dynamics in pancreatic
β-cells. Incretin hormones such as glucagon-like peptide 1 (GLP-1) increase cAMP and augment
insulin secretion in pancreatic β-cells. Imaging experiments performed in MIN6 ... Cited by 3 - Related articles - BL Direct - All 4 versions
- ►nih.gov D Russell-Jones, A Vaag, O Schmitz, BK Sethi, N Lalic, … - Diabetologia, 2009 - Springer Abstract Aims/hypothesis The aim of the study was to compare the efficacy and safety of liraglutide
in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human
insulin), all in combination with metformin and glimepiride. Methods This randomised ... Cited by 7 - Related articles - All 3 versions
J de Heer, J Pedersen, C Ørskov, JJ Holst - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Glucagon-like peptide-2 (GLP-2) is a gut hormone regulating intestinal
growth and nutrient absorption. Recently, GLP-2 has been reported to stimulate glucagon secretion
in healthy humans. We sought to clarify the mech- anism and physiological significance of ... Cited by 2 - Related articles - BL Direct - All 3 versions
